Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly;Alterações morfológicas e funcionais cardíacas e análise dos fatores determinantes de hipertrofia ventricular esquerda em 40 pacientes com acromegalia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 1, 2006, Pages 82-90

  Casini, Alessandra Ferri ^a   Araújo, Paula Bruna ^a   Fontes, Rosita ^a   Xavier, Sérgio Salles ^a   Gadelha, Mônica R ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Acromegaly; Cardiomyopathy; Echocardiogram; Left ventricular hypertrophy

Indexed keywords

EID: 33646740349     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302006000100012     Document Type: Article

References (43)

1. Swearing B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
2. Ayuk J, Clayton RN, Holtder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-7.
3. Bates AS, Vant'Hoff W, Jones JM, Clayton R. An audit of outcome of treatment in acromegaly. Quarter J Med 1993;86:293-9.
4. Rajassorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.
5. Orme SM, Mchally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-4.
6. Holdaway IM, Rajassorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74.
7. López-Velasco R, Escobar-Morreale HF, Veja B, Villa E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997;82:1047-53.
8. Ciulla M, Arosio M, Barelli MV, Paliotti R, Porretti S, Valentini P, et al. Blood pressure-independent cardiac hypertrophy in acromegalic patients. J Hypertens 1999;17:1965-9.
9. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and heart. Clin Endocrinol 2001;54:137-54.
10. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15:555-73.
11. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients. Am Heart J 1980;100:41-52.
12. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferono D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193-9.
13. Rodrigues EA, Caruana MP, Lahiri A, Nabaro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle. Br Heart J 1989;62:185-94.
14. Pereira AM, Van Thiel SW, Linder JR, Roelfsema F, Van Der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004;89:71-5.
15. Bondanelli M, Ambrosio MR, Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4:239-49.
16. Donangelo I, Une K, Gadelha M. Diagnóstico e tratamento da acromegalia no Brasil. Arq Bras Endocrinol Metab 2003;47:331-46.
17. Corrêa FHS, Tabet ALO. Prevalência de diabetes mellitus na acromegalia: Nossa experiência. Arq Bras Endocrinol Metab 2003;47:331-46.
18. a ed., Rio de Janeiro: Guanabara Koogan 2001. pp.302-10.
19. Vitale G, Galderisi M, Pivonello R, Spinelli L, Ciccarelli A, De Divittis A, et al. Prevalence and determinants of left ventricular hypertrophy in acromegaly: Impact of different methods of indexing left ventricular mass. Clin Endocrinol 2004;60:343-9.
20. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analogue sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-40.
21. Minitti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Fenetti E, Cassone R, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalic. Clin Endocrinol 1998;49:101-6.
22. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 2003;58:169-76.
23. Fazio S, Cittadini A, Cuocolo A, Merola B, Sabatini D, Colao A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994;79:441-5.
24. Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, Boné F, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000;85:179-82.
25. Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F, et al. Cell death in acromegalic cardiomyopathy. Circulation 1999;99:1426-34.
26. Ciulla M, Epaminonda P, Paliotti R, Barelli MV, Ronchi C, Cappiello V, et al. Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: Effects of treatment. Eur J Endocrinol 2004;151:179-86.
27. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: An observational analytical casecontrol study. J Clin Endocrinol Metab 2003;88:3196-201.
28. Bihan H, Espinosa C, Valdes-Socian H, Salenare S, Young J, Levasseur S, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004;89:5308-13.
29. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;3:51-6.
30. Herrmann BL, Bruch C, Saller B, Ferdin S, Dagrest N, Ose C, et al. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol 2001;55:201-7.
31. Colao A, Spinelli L, Cuocolo A, Spiezia S, Piovonello R, Di Somma C, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002;87:3097-104.
32. Luna RL, Castro I. Hipertensão arterial sistêmica. Batlouni M, Cantarelli E, Ramirez JAF, Luna RL, Feitosa GS, eds. Cardiologia, princípios e prática, 1a ed., São Paulo: Artmed, 1999. pp.791-814.
33. a ed., Rio de Janeiro: Guanabara Koogan, 2001. pp.952-63.
34. Devereux R. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization and comparison to other methods. Hypertension 1987;9:19-26.
35. a ed., New York: Lea & Fabiger, 1994. p.658.
36. Amico AF, Lichtenberg GS, Reisner SA, Stone CK, Schwartz RG, Meltzer RS. Superiority of visual versus computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. Am Heart J 1989;118:1259-65.
37. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimante L, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84:17-23.
38. Vianna CB, Vieira MC, Mady C, Liberman B, Durazzo AS, Knoepfelmacker M, et al. Treatment of acromegaly improves myocardial abnormalities. Am Heart J 2002;143:873-6.
39. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Internal Med 1990;113:921-5.
40. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte MD, et al. Is the acromegalic cardiomyopathy reversible? Effects of 5 years normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86:1551-7.
41. Casini AF, Taboada GF, Van Haute FRB, Almeida CA, Correa LL, Lima GAB, et al. Efeito de seis meses de tratamento com octreotide LAR® na função cardiovascular em pacientes acromegálicos. Arq Bras Endocrinol Metab 2004;48:593.
42. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte MD, et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J Clin Endocrinol Metab 1999;84:1518-23.
43. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-96.